Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single and Multiple Ascending Dose Study of TAK-137 in Healthy Male Subjects
jRCT2080222630Phase 1
- Sponsor
- Takeda
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-137 (4 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of TAK-137 and Pharmacokinetics of TAK-137.
02
Drugs
TAK-137
Beyond the preview
Go deeper on jRCT2080222630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222630.